Recent research is increasingly exploring the potential of psychedelics in treating depression and other mental health disorders. A new study has identified a “neural fingerprint” shared by five widely recognized psychedelics.
Typically, the effects of these substances are studied in small groups and separately. An international team of researchers aimed to understand their collective impacts by examining them as a group.
The study focused on five psychedelics: psilocybin, LSD (Lysergic Acid Diethylamide), mescaline, DMT (dimethyltryptamine), and ayahuasca.
Utilizing fMRI brain scans from individuals who had consumed these drugs, the researchers discovered two common patterns: enhanced communication between distinct brain networks and selective reductions in connectivity within certain networks.
“This is a breakthrough in how we think about psychedelic drugs,” says Danilo Bzdok from McGill University in Canada.
“For the first time, we show there’s a common denominator among drugs that we currently consider completely separate.”
The study involved 11 separate datasets, encompassing 267 individuals from five countries, resulting in a total of 519 brain scans.
The researchers observed increased interconnectivity in the cortical brain networks responsible for higher-level thinking, as well as regions associated with sight and touch, which aligns with the experiences reported during psychedelic trips.
Changes in connectivity were also noted in deeper brain areas like the caudate, putamen, and cerebellum, which are involved in coordinating perception and action.
This enhanced interaction suggests a flattening of the brain’s usual hierarchy, according to the researchers. Recognizing this commonality across various psychedelics could aid in their development as treatments and in understanding hallucinations’ biology.
Among the psychedelics studied, psilocybin and LSD showed the most similar neural patterns, reflecting their comparable chemical structures and the experiences they induce.
“This approach gives us an X-ray view of the entire research community,” says Bzdok.
Taking a broader perspective allows researchers to connect significant insights, which was previously challenging due to restrictions around drug studies and their associations with criminalization and counterculture.
Today, controlled and safe research projects are more prevalent. Initial studies have linked psychedelics to immune system modulation and lasting mood improvements.
Earlier research also indicates that psychedelics might slow biological aging and even lower crime rates.
While it’s clear these substances alter the mind, the challenge is to design and use them beneficially, such as for treating depression or substance use disorders.
By systematically comparing these drugs, the study offers a new perspective. Its findings challenge previous studies that suggested these substances disrupted brain connectivity, instead highlighting selective within-network changes alongside stronger cross-network communication.
The next step for researchers is to conduct standardized tests on larger groups to further examine these brain patterns.
Related: Single Dose of DMT Rapidly Reduces Symptoms of Major Depression
It’s important to note that the datasets analyzed differed in methods, doses, timings, and drugs used, which future research can address to minimize variations.
This study didn’t focus on how these drugs could be used as treatments, but that is a potential area for future exploration.
“Many drug therapies for depression, for example, have changed little over the past decades,” says Bzdok.
“Psychedelics may represent the most promising shift in mental health treatment since the 1980s.”
The research findings have been published in Nature Medicine.
